लोड हो रहा है...
New hope for chronic myelogenous leukemia patients: dasatinib offers better efficacy with shorter treatment
Although the discovery of tyrosine kinase inhibitors (TKIs) has dramatically improved the prognoses of chronic myelogenous leukemia (CML) patients, a cure has remained elusive. Unanswered questions include how long must a patient continue on TKI therapy, and how does a patient know when he/she can s...
में बचाया:
| में प्रकाशित: | Stem Cell Investig |
|---|---|
| मुख्य लेखकों: | , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
AME Publishing Company
2016
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4958058/ https://ncbi.nlm.nih.gov/pubmed/27488943 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/sci.2016.05.05 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|